Abstract
Background. We investigated retrospectively the usefulness of polysaccharide K (PSK) administration for prolonging survival after noncurative resection in patients with stage IV gastric cancer who underwent surgery at our department.
Methods. 357 patients with gastric cancer evaluated as stage IV according to thegeneral rules for gastric cancer study, 11th edn (1985) of the Japanese Research Society for Gastric Cancer, who were expected to succumb to surgical death or postoperative death within 2 months were studied. The patients were divided into two groups: total PSK dosage greater than or less than 180g. Survival rates were calculated for each group.
Results. In these stage-IV gastric cancer patients, the 5-year and 10-year survival rates in the PSK group were both 13.9%. In the non-PSK group, the rates were 8.7% and 7.0%, respectively. The survival rates were significantly higher in the PSK group (p = 0.0001). The survival rate was also calculated with respect to the staging factors. Patients in the PSK group who had H0, P0, se or milder and n3 or n4 showed a significantly higher survival rate than those with these staging factors in the non-PSK group (p = 0.010).
Conclusion. PSK administration prolonged survival in stage-IV gastric cancer patients, the effect being marked in patients with severe lymph node metastasis. We suggest that be administered as adjuvant therapy in stage-IV gastric cancer patients with severe lymph node metastasis (n3, n4).
Similar content being viewed by others
References
Ohtsu A, Yoshida S, Miyata Y, Shimada Y (1995) Recent advances in chemotherapy for advance gastric cancer: From the standpoint of survival advantage. Jpn J Cancer Chemother 22:444–450
Iwanaga T, Hiratuka M, Furukawa H, et al. (1992) Extensive radical surgery and its result: Multi organ resection in the surgery of gastric cancer (in Japanese). Gekashinryo 34:55–62
Nakazato H, Koike A, Saji S, et al. (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122–1126
Japanese Research Society for Gastric Cancer (1985) The general rules for gastric cancer study, March 1985 11th edn (in Japanese). Kanehara, Tokyo
Glasgow AH, Nimberg RB, Menzoian JO, et al. (1974) Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. N Engl J Med 98:413–421
Nomoto K, Tsuru S, Awane Y, et al. (1986) Changes of nonspecific suppressor factors in the serum of gastric cancer patients after surgery and immunochemotherapy. Jpn J Cancer Chemother 13:458–463
Kondo Y, Uchino J, Sawaguchi Y, et al. (1996) Evalution of Multi Skin Test in colorectal cancer patients and effects of serum immunosuppressive factor and cytokine production of peripheral mononuclear cells. Am J Clin Oncol 19:159–163
Sekizuka H, Suguro K, Haruyama S, et al. (1985) Cellular immunity in postoperative patients of gastric cancer; the effect of immunomodulators (in Japanese). Jpn J Cancer Clin 31:1381–1386
Harada M, Matsunaga K, Oguchi Y, et al. (1995) The involvement of transforming growth factor β in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res 55:6146–6151
Saji S, Sugiyama Y, Kunieda K (1994) Cyotokine response induced by surgical stress (in Japanese). Surgery Frontier 1:7–13
Hersh EM (1974) Immunosuppressive agents. In: Sartoli AC, Jhons DG (eds) Antineoplastics and immunosuppressive agents. I. Springer, New York, pp 577–617
Saji S, Kida T, Kunieda K, et al. (1985) Five-year survival of gastric cancer patients treated with postoperative long term adjuvant immunochemotherapy. Prog Med 5:485–492
Saji S, Takao H, Kida T, et al. (1987) Effects of postoperative adjuvant immunochemotherapy using PSK for patients of gastric cancer, and its preventive effects on the recurrence. Prog Med 8:1703–1709
Kabe S, Tamakuma M, Mimura K, et al. (1985) Controlled study in stage IV gastric cancer of adjuvant immunochemotherapy with chemotherapy (in Japanese). Jpn J Cancer Clin 31:1805–1809
Mitomi T, Ogoshi K (1986) Clinical Study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer. Jpn J Cancer Chemother 13:2532–2537
Vanky F, Wang P, Klein E (1992) The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumor cells. Cancer Immunol Immunother 35:193–198
Nio Y, Shiraishi T, Tsubono M, et al. (1991) In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 32:335–341
Fujii M, Fujii T, Saito K, et al. (1987) Tumor growth promoting activity of an immunosuppressive substance and its modulation by protein-bound polysaccharide PSK. Immun Lett 15:347–351
Hattori T, Nakajima T, Nakazato H, et al. (1990) Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 20:127–136
Ebina T, Kohya H, Ishikawa K (1989) Antitumor effect of PSK: Role of regional lymph nodes and enhancement of concomitant and sinecomitant immunity in the mouse. Jpn J Cancer Res 80:158–166
Okabayashi T, Horimi T, Gouchi A, et al. (1986) Immunohistochemical analysis of regional lymph nodes in gastric cancer (in Japanese). Jpn J Gastroenterol Surg 19:844–848
Author information
Authors and Affiliations
About this article
Cite this article
Kuroda, Y., Horikawa, N., Tsuji, M. et al. Usefulness of polysaccharide K (PSK) as postoperative adjuvant immunotherapy in patients with stage IV gastric cancer. Int J Clin Oncol 3, 311–316 (1998). https://doi.org/10.1007/BF02628052
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02628052